Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF | R&D Systems 349-F4 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

catalog :

349-F4

quantity :

50 ug

price :

369 USD

citations: 15

Reference
Zhang J, Li H, Wu Q, Chen Y, Deng Y, Yang Z, et al. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth. Redox Biol. 2019;22:101116 pubmed publisher
Mamer S, Chen S, Weddell J, Palasz A, Wittenkeller A, Kumar M, et al. Discovery of High-Affinity PDGF-VEGFR Interactions: Redefining RTK Dynamics. Sci Rep. 2017;7:16439 pubmed publisher
Davydova N, Harris N, Roufail S, Paquet Fifield S, Ishaq M, Streltsov V, et al. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. J Biol Chem. 2016;291:27265-27278 pubmed publisher
Kerr L, Donoghue J, Wilding A, Johns T. Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma. Sarcoma. 2016;2016:3484673 pubmed
Han K, Chang J, Lee H, Azar D. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci. 2016;57:3313-22 pubmed publisher
Harris N, Davydova N, Roufail S, Paquet Fifield S, Paavonen K, Karnezis T, et al. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem. 2013;288:8176-86 pubmed publisher
Tabata T, Petitt M, Fang Hoover J, Rivera J, Nozawa N, Shiboski S, et al. Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol. 2012;181:1540-59 pubmed publisher
Chien M, Ku C, Johansson G, Chen M, Hsiao M, Su J, et al. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis. 2009;30:2005-13 pubmed publisher
Mouawad R, Spano J, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer. 2009;45:1407-14 pubmed publisher
Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol. 2008;10:527-37 pubmed publisher
Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 2007;204:1431-40 pubmed
Red Horse K, Rivera J, Schanz A, Zhou Y, Winn V, Kapidzic M, et al. Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation. J Clin Invest. 2006;116:2643-52 pubmed
Le Bras B, Barallobre M, Homman Ludiye J, Ny A, Wyns S, Tammela T, et al. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nat Neurosci. 2006;9:340-8 pubmed
Lin J, Lalani A, Harding T, Gonzalez M, Wu W, Luan B, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005;65:6901-9 pubmed
Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith D, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003;104:603-10 pubmed

product information

brand :

R&D Systems

master code :

349-F4

SKU :

349-F4-050

product name :

Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF

description :

The Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human VEGFR3/Flt-4 Fc Chimera Protein, CF has been validated for the following applications: Binding Activity.

target :

VEGFR3/Flt-4

category :

Proteins and Enzymes

unit size :

50 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

145-150 kDa, 90-95 kDa and 75-80 kDa, reducing conditions

theoretical molecular weight :

112 kDa (monomer)

gene symbol :

FLT4

details of functionality :

Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGFR3/Flt-4 Fc Chimera at 5 µg/mL (100 µL/well) binds Recombinant Human VEGF-D (Catalog # 622-VD) with an apparent Kd 15 nM.

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

catalog number base :

349-F4

accessionNumbers :

P35916

applications :

Binding Activity

source :

Mouse myeloma cell line, NS0-derived human VEGFR3/Flt-4 protein Human Flt-4 (Tyr25-Ile776) (Ser473-Ile776) Accession # P35916 IEGRDMD Human IgG1 (Pro100-Lys330) 6-His tag N-terminus C-terminus

2020 USD :

369

2021 USD :

369 USD

alt names :

EC 2.7.10, EC 2.7.10.1, Flt-4, FLT4, fms-related tyrosine kinase 4, LMPH1A, PCLFLT41, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, Tyrosine-protein kinase receptor FLT4, vascular endothelial growth factor receptor 3, VEGF R3, VEGFR-3, VEGFR3Fms-like tyrosine kinase 4

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.